Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12605000719639
Ethics application status
Approved
Date submitted
31/10/2005
Date registered
8/11/2005
Date last updated
14/01/2009
Type of registration
Retrospectively registered
Titles & IDs
Public title
A comparison of high flow nasal oxygen to high flow face mask oxygen in recently extubated patients.
Query!
Scientific title
A randomised crossover trial comparing the efficacy of the Fisher & Paykel Healthcare High Flow Nasal Interface (HFNO) to Hudson Face Mask (FMO) in maintaining PaO2 saturations in recently extubated patients requiring supplemental oxygen to treat hypoxia.
Query!
Secondary ID [1]
219
0
Clinical Study number 2005-16
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hypoxia
869
0
Query!
Condition category
Condition code
Respiratory
936
936
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
During a 30 minute washout period post-extubation, patients will be titrated to receive a fraction of oxygen (FiO2) at a flow rate of 30 lpm. At the end of this period an arterial blood gas sample will be taken. Patients will then be randomised to receive either FMO or HFNO. The FiO2 and flow rate will remain the same. At the end of 30 minutes an ABG will be taken. Patients will then crossover to receive the other mode for 30 minutes with an ABG taken at the end of the period.
The FMO group will have oxygen supplied via a Hudson Face Mask and a Fisher & Paykel Healthcare MR850 humidifier. The HFNO group will have oxygen supplied via a Fisher & Paykel Healthcare MR880 humidification system.
Query!
Intervention code [1]
743
0
Treatment: Devices
Query!
Comparator / control treatment
Standard oxygen therapy with Hudson face mask. A Hudson face mask is a simple oxygen mask. (The high flow nasal interface in a wide bore nasal cannula)
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
1231
0
Arterial blood gas
Query!
Assessment method [1]
1231
0
Query!
Timepoint [1]
1231
0
Samples will be taken at 30 minutes after each time treatment has been given.
Query!
Secondary outcome [1]
2243
0
Endpoints include heart rate, blood pressure, respiratory rate, ability to tolerate mode (nurse assessed).
Query!
Assessment method [1]
2243
0
Query!
Timepoint [1]
2243
0
Secondary endpoints will be measured at the same time points as ABG sampling is performed.
Query!
Secondary outcome [2]
2244
0
Patient reported comfort will be obtained once the patient is able to talk clearly.
Query!
Assessment method [2]
2244
0
Query!
Timepoint [2]
2244
0
When patients are able to talk clearly
Query!
Eligibility
Key inclusion criteria
Patients meeting extubation criteria whose families provide consent and later give delayed consent.
Query!
Minimum age
Not stated
Query!
Query!
Maximum age
Not stated
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients who do not consent; patients with DNR order.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Sealed opaque envelope
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generation with blocking also used
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
11/07/2005
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
50
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
1036
0
Commercial sector/Industry
Query!
Name [1]
1036
0
Fisher and Paykel Healthcare
Query!
Address [1]
1036
0
15 Maurice Paykel Place. East Tamaki. Auckland
Query!
Country [1]
1036
0
New Zealand
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Fisher and Paykel Healthcare
Query!
Address
15 Maurice Paykel Place. East Tamaki. Auckland 2013
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
898
0
None
Query!
Name [1]
898
0
none
Query!
Address [1]
898
0
Query!
Country [1]
898
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
2335
0
Peninsula Health,
Query!
Ethics committee address [1]
2335
0
Query!
Ethics committee country [1]
2335
0
Australia
Query!
Date submitted for ethics approval [1]
2335
0
Query!
Approval date [1]
2335
0
Query!
Ethics approval number [1]
2335
0
Query!
Ethics committee name [2]
2336
0
Frankston Intensive Care Unit
Query!
Ethics committee address [2]
2336
0
Query!
Ethics committee country [2]
2336
0
Australia
Query!
Date submitted for ethics approval [2]
2336
0
Query!
Approval date [2]
2336
0
Query!
Ethics approval number [2]
2336
0
Query!
Summary
Brief summary
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
35373
0
Query!
Address
35373
0
Query!
Country
35373
0
Query!
Phone
35373
0
Query!
Fax
35373
0
Query!
Email
35373
0
Query!
Contact person for public queries
Name
9932
0
Catherine Gerard
Query!
Address
9932
0
15 Maurice Paykel Place
East Tamaki Auckland
Query!
Country
9932
0
New Zealand
Query!
Phone
9932
0
+64 9 5740100
Query!
Fax
9932
0
Query!
Email
9932
0
[email protected]
Query!
Contact person for scientific queries
Name
860
0
Dr Nina Fowler
Query!
Address
860
0
Intensive Care Unit
Frankston Hospital
PO Box 52
Frankston VIC 3199
Query!
Country
860
0
Australia
Query!
Phone
860
0
+61 3 97848567
Query!
Fax
860
0
Query!
Email
860
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF